Presentation is loading. Please wait.

Presentation is loading. Please wait.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Published byBrian Dufour Modified over 6 years ago

Similar presentations

Presentation on theme: "Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous."— Presentation transcript:

1 Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?  Laura Londra, M.D., Caroline Moreau, M.D., M.P.H., Ph.D., Donna Strobino, Ph.D., Aarti Bhasin, M.D., M.P.H., Yulian Zhao, M.D., Ph.D., H.C.L.D.  Fertility and Sterility  Volume 106, Issue 3, Pages (September 2016) DOI: /j.fertnstert Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

2 Figure 1 Description of the process for the selection of the cohort of cycles. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous."

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Ectopic pregnancy rate increases with the number of retrieved oocytes in autologous in vitro fertilization with non-tubal infertility but not donor/recipient.

Ectopic pregnancy rate increases with the number of retrieved oocytes in autologous in vitro fertilization with non-tubal infertility but not donor/recipient.
Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H. 

Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H. 
Wendy S. Vitek, M. D. , Jeannine Witmyer, Ph. D. , Sandra A. Carson, M

Wendy S. Vitek, M. D. , Jeannine Witmyer, Ph. D. , Sandra A. Carson, M
Laura Londra, M. D. , Caroline Moreau, M. D. , M. P. H. , Ph. D

Laura Londra, M. D. , Caroline Moreau, M. D. , M. P. H. , Ph. D
A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome?  Ronit Machtinger, M.D., Joseph.

A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome?  Ronit Machtinger, M.D., Joseph.
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.

Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.

No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
Extremities of body mass index and their association with pregnancy outcomes in women undergoing in vitro fertilization in the United States  Jennifer.

Extremities of body mass index and their association with pregnancy outcomes in women undergoing in vitro fertilization in the United States  Jennifer.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Michael M. Alper, M.D.  Fertility and Sterility 

Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day.

Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day.
Ovarian pregnancy after in vitro fertilization

Ovarian pregnancy after in vitro fertilization
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 

Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
Medical treatment of ectopic pregnancy: a committee opinion

Medical treatment of ectopic pregnancy: a committee opinion

Similar presentations

Ads by Google